Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Non-Current AssetsPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury Shares
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

BioCorRx (BICX) Other Non-Current Assets (2016 - 2025)

Historic Other Non-Current Assets for BioCorRx (BICX) over the last 15 years, with Q3 2025 value amounting to $5.9 million.

  • BioCorRx's Other Non-Current Assets rose 1166974.18% to $5.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $5.9 million, marking a year-over-year increase of 1166974.18%. This contributed to the annual value of $49784.0 for FY2024, which is 702.75% down from last year.
  • Latest data reveals that BioCorRx reported Other Non-Current Assets of $5.9 million as of Q3 2025, which was up 1166974.18% from $6.0 million recorded in Q2 2025.
  • In the past 5 years, BioCorRx's Other Non-Current Assets registered a high of $6.0 million during Q1 2025, and its lowest value of $29700.0 during Q2 2022.
  • Its 5-year average for Other Non-Current Assets is $1.3 million, with a median of $54431.0 in 2023.
  • Its Other Non-Current Assets has fluctuated over the past 5 years, first plummeted by 9577.62% in 2022, then surged by 1180196.18% in 2025.
  • Quarter analysis of 5 years shows BioCorRx's Other Non-Current Assets stood at $703158.0 in 2021, then plummeted by 85.39% to $102706.0 in 2022, then plummeted by 47.86% to $53547.0 in 2023, then dropped by 7.03% to $49784.0 in 2024, then surged by 11739.48% to $5.9 million in 2025.
  • Its last three reported values are $5.9 million in Q3 2025, $6.0 million for Q2 2025, and $6.0 million during Q1 2025.